One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
|Articles|April 6, 2007
New findings help tailor drug therapies for men with LUTS
Medical therapy has a long history as a first-line treatment for men with lower urinary tract symptoms, and recent data have brought into focus which drugs work best for which men, according to Claus G. Roehrborn, MD, of the University of Texas Southwestern Medical Center in Dallas. Combination therapy-not necessarily the combination that urologists are most familiar with-also plays an important role.
Advertisement
Advertisement
Related to this article
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
2
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
3
AACU, WOCN Society urge safeguards in Medicare catheter bidding
4
The Evolving Landscape of Minimally Invasive BPH Therapy
5